The search for an HIV prevention vaccine: latest news

The search for an HIV prevention vaccine resources

  • Vaccines

    HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection....

    From: Preventing HIV

    Information level Level 4
  • Vaccines

    The promise of an effective HIV vaccine has always been just over the horizon, but more than 20 years after the identification of HIV, vaccines...

    From: HIV transmission & testing

    Information level Level 4

The search for an HIV prevention vaccine features

The search for an HIV prevention vaccine news from aidsmap

More news

The search for an HIV prevention vaccine news selected from other sources

  • China to launch clinical trial of long-lasting HIV vaccine: paper

    Chinese scientists will begin the second-phase clinical trial of an HIV vaccine on 160 volunteers, Friday's China Daily reported. The candidate vaccine, DNA-rTV, relies on replication of the DNA of HIV to stimulate effective immunization.

    20 July 2019 | Xinhua
  • HIV Vaccine Trials on Gay, Bi Men to Begin in U.S., Europe

    Around 3800 men who have sex with men will be part of Johnson & Johnson's historic vaccine trial.

    15 July 2019 |
  • J&J’s Quest for Elusive HIV Vaccine Is Poised for Major Test

    Johnson & Johnson is preparing to test an experimental HIV vaccine in the U.S. and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration.

    15 July 2019 | Bloomberg
  • Scripps Research-led consortium receives $129 million NIH award to bring new HIV vaccination approach into clinical testing

    The candidate vaccine products are designed to be administered in multiple stages to induce immune system proteins called broadly neutralizing antibodies (bnAbs). In multiple animal studies, bnAbs have been shown to provide long-lasting protection against exposure to multiple HIV strains.

    12 July 2019 | Scripps Institute
  • HVTN's large-scale HIV vaccine efficacy trials fully enrolled

    The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, has fully enrolled its four ongoing large-scale HIV vaccine efficacy trials. The clinical trials, underway on four continents in 12 countries, are made possible by 12,669 study participants and the collaborative efforts of HVTN study teams, all on a journey to find a safe and effective HIV vaccine. Complete enrollment facilitates the collection and analysis of trial-specific data, enabling researchers to answer research questions.

    24 June 2019 | HIV Vaccine Trials Network
  • Low trust in vaccines 'a global crisis'

    Public mistrust of vaccines means the world is taking a step backwards in the fight against deadly yet preventable infectious diseases, warn experts. A Wellcome Trust analysis includes responses from more than 140,000 people in over 140 countries. Eastern Europe was the world region most sceptical of vaccines, with only 50% of people confident vaccines were safe, with Western Europe in second place, at 59%. People in France were also among the most likely to disagree that vaccines were effective, at 19%, and to disagree that vaccines were important for children to have, at 10%. The World Health Organization lists vaccine hesitancy as one of the top 10 threats to global health.

    19 June 2019 | BBC
  • The three big studies pushing at the frontiers of HIV prevention

    These trials are being conducted under the auspices of the HIV Vaccine Trials Network. The network currently runs 49 clinical trial sites in nine countries with 18 ongoing trials, four of which are efficacy trials. Three trials are of particular interest as they have already been running since 2016 and are expected to close in late 2021.

    16 June 2019 | The Conversation
  • Johnson & Johnson Announces Full Enrollment in Proof-of-Concept Efficacy Study of Janssen’s Investigational HIV Preventive Vaccine

    Phase 2b efficacy study of mosaic-based vaccine successfully enrolls 2,600 women aged 18-35 across five southern African countries

    31 May 2019 | Janssen press release
  • Will a vaccine crisis of confidence impact the global response to HIV?

    Mitchell Warren of AVAC: "The implications of the anti-vaccination movement are enormous. Just as vaccines against some of the greatest global killers finally come within reach, fear and misinformation could diminish vital commitments to continued vaccine research, and important investments in vaccine education and delivery."

    20 May 2019 | Science Speaks
  • Despite Uptick, Black and Latinx People Have Relatively Low Participation in HIV Vaccine Trials

    Black and Latinx people historically have not willfully participated in clinical trials in high numbers. Medical mistrust of research and health care institutions has long been a problem for conducting biomedical research. So what's causing the racial disparities in research participation, and what are researchers doing about it?

    14 May 2019 | The Body Pro
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.